Syros Pharmaceuticals (SYRS): Deerfield Management Discloses Position

Page 2 of 14

Page 2 of 14 – SEC Filing
CUSIP No.
87184Q107
13G
Page 2 of 11 
1.
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Deerfield Mgmt, L.P.
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
  (a) o
  (b) ý
3.
SEC USE ONLY
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware


NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
SOLE VOTING POWER
 
0
6.
SHARED VOTING POWER
 
628,566 (1)
7.
SOLE DISPOSITIVE POWER
 
0
8.
SHARED DISPOSITIVE POWER
 
628,566 (1)
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
628,566 (1)
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
o
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
2.69%
12.
TYPE OF REPORTING PERSON*
 
PN
__________________
(1) Comprised of Common Stock held by Deerfield Special Situations Fund, L.P. of which Deerfield Mgmt, L.P. is the general partner.

Follow Syros Pharmaceuticals Inc.

Page 2 of 14